A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

NCT02158936 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytopaenia

Interventions

DRUG: Eltrombopag
DRUG: Azacitidine
DRUG: Placebo
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals